In vitro activity of antimicrobial agents against clinical isolates of Pseudomonas aeruginosa

Japanese Journal of Antibiotics

Volumn 58, Issue 5, 2005, Pages 445-451

  Abe, Noriyuki ^a   Komatsu, Masaru ^a   Iwasaki, Mizuho ^a   Nagasaka, Yoko ^a   Fukuda, Saori ^a   Matsuo, Shuji ^a   Shimakawa, Koichi ^b  

^a TENRI HOSPITAL   (Japan)

^b SHIONOGI AND CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; AZTREONAM; BIAPENEM; CEFEPIME; CEFOZOPRAN; CEFPIROME; CEFTAZIDIME; CIPROFLOXACIN; GATIFLOXACIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PANIPENEM; PAZUFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; PRULIFLOXACIN; SULPERAZON;

ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; DNA FINGERPRINTING; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PSEUDOMONAS AERUGINOSA; RANDOM AMPLIFIED POLYMORPHIC DNA;

ANTI-BACTERIAL AGENTS; CARBAPENEMS; CEPHALOSPORINS; FLUOROQUINOLONES; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA;

EID: 28244474505     PISSN: 03682781     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved-6th edition. NCCLS document M7-A6, 2003, Wayne, Pa, USA
2. ARAKAWA, Y.; N. SHIBATA, K. SHIBAYAMA, et al. : Convenient test for screening metallo-beta-lactamase-producing gram-negative bacteria by using thiol compounds. J Clin. Microbiol. 38: 40-43, 2000
3. ESHWAR, M.; E. C. MAUREEN, F. JENNIFER, et al.: Random amplified polymorphic DNA typing of Psedomonas aeruginosa isolates recovered from patients with cystic fibrosis. J. Clin. Microbiol. 34: 1129-1135, 1996
4. Jpn. J. Antibiotics 56:341-362,2003
5. SHENG, W. H.; Y. C. CHEN, J. T. WANG, et al.: Emerging fluoroquinolone-resistance for common clinically important gram-negative bacteria in Taiwan. Diagn. Microbiol. Infect. Dis. 43: 141-147,2002
6. AUBERT, G.; A. CARRICAJO, A. C. VAUTRIN, et al: Impact of restricting fluoroquinolone prescription on bacterial resistance in an intensive care unit. J. Hosp. Infect. 59: 83-89, 2005
7. FUKUOKA, T.; S. OHYA, T. NARITA, et al: Activity of the carbapenem panipenem and role of the OprD (D2) protein in its diffusion through the Pseudomonas aeruginosa outer membrane. Antimicrob. Agents Chemother. 37: 322-327, 1993
8. KÖHLER, T.; M. MICHEA-HAMZEHPOUR, S. F. EPP, et al: Carbapenem activities against Pseudomonas aeruginosa: Respective contributions of OprD and efflux systems. Antimicrob. Agents Chemother. 43: 424-427, 1999
9. LIVERMORE, D. M.: Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? Clin. Infect. Dis. 34: 634-640, 2002
10. GRUSON, D.; G. HILBERT, F. VARGAS, et al.: Rotation and restricted use of antibiotics in a medical intensive care unit. Am. J. Respir. Crit. Care Med. 162: 837-843, 2000
11. MATTOES, H. M.; B. CAPITANO, M. K. KIM, et al: Comparative pharmacokinetic and pharmacodynamic profile of piperacillin/tazobactam 3.375G Q4H and 4.5G Q6H. Chemotherapy 48: 59-63, 2002
12. CRAIG, A.: Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26: 1-12, 1998
13. Jpn. J. Antibiotics 56: 697-704, 2003
14. HISAAKI, N.; M. KOMATSU, N. SHIBATA, et al. : Metallo-β-lactamase- producing gram-negative bacilli: laboratory-based surveillance in cooperation with 13 clinical laboratories in the kinki region of Japan. J. Clin. Microbiol. 42: 5256-5263, 2004
15. J. Antibiotics 57: 70-104, 2004